Skip to content

The Evaluation of Effect of Sanyinjiao (SP6) Acupressure on Early Diabetic Nephropathy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02501772
Enrollment
60
Registered
2015-07-17
Start date
2014-09-30
Completion date
2019-12-31
Last updated
2019-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Nephropathy

Brief summary

For diabetic patient with persisted albuminuria under the intensive control on blood pressure and blood glucose, the non-invasive method of acupressure at Sanyinjiao (SP6) is easy to use and significantly effect on albuminuria reduction in patients of diabetic nephropathy.

Interventions

DEVICEacupressure by ankle band

Sponsors

Mackay Memorial Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. age between 20 and 80 years old; 2. HbA1c was lower than 9% according to the NGSP(National Glycohaemoglobin Standardisation Programme); 3. estimated glomerular filtration rate (eGFR) was more than 60 mL/min/1.73 m2.

Exclusion criteria

1. Hyperglycemic crisis, including HHS(hyperglycemic hyperosmolar syndrome) and DKA(diabetic ketoacidosis ); 2. Persist diabetes poorly control, Hemoglobin A1c \[HbA1c\] \>9%; 3. Endocrine disorders: such as abnormal function of thyroid, pituitary, and sex glands; 4. heart diseases:such as arrhythmia, myocardial infarction, heart failure, or installed pacemaker; 5. immune and allergic diseases: such as systemic lupus erythematosus and asthma; 6. liver or kidney dysfunction: GOT or GPT(glutamate-pyruvate transaminase ) \> 80 IU/L, eGFR\<60 (mL/min); 7. pregnant or lactating women; 8. less than 6months postpartum; 9. acute illness, fever, Lower urinary tract infection, NSAID(nonsteroidal antiinflammatory drug) administration; 10. physical dysfunction because of stroke.

Design outcomes

Primary

MeasureTime frame
urinary spot albumin creatine excretion ratio (UACR) change8 week duratoin

Countries

Taiwan

Contacts

Primary ContactShih-Ming Chuang
gopacer@hotmail.com886-919652673

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026